News in English

RIYADH, Saudi Arabia--(BUSINESS WIRE)--Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE:TDY), announced that it has appointed Tarik Solomon as managing director for the Middle East and North Africa (MENA). Based in Riyadh, Solomon will oversee the company’s regional growth strategy, partnerships, and localization initiatives across defense, industrial, and emerging technology sectors. He will report to Dr. JihFen Lei, president of Teledyne FLIR Defense. Teledyne Technolog...

LOS ANGELES--(BUSINESS WIRE)--In the shadow of the Hollywood Bowl, hotel workers at the Hilton Garden Inn hotel in Hollywood started a picket line at 6 AM local time today. The 160-room hotel, owned by RLJ Lodging Trust and operated by Aimbridge Hospitality, expected high occupancy this weekend for one of the last Hollywood Bowl concerts of the year. In Philadelphia, workers at the Wyndham Historic District hotel—also owned by RLJ Lodging Trust and operated by Aimbridge—walked off the job earli...

NEW YORK--(BUSINESS WIRE)--ByHeart, a next-generation baby nutrition company, announced today that, out of an abundance of caution, it has chosen to voluntarily recall two batches of ByHeart Whole Nutrition Infant Formula following notification from the U.S. Food and Drug Administration (FDA) of a broader ongoing investigation into a recent outbreak of infant botulism. Infant botulism is a rare but potentially fatal illness that presents a serious threat to the health of infants which occurs wh...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas. Pove is an investigational recombinant fusion protein therapeutic and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove is the on...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. Data from cardiovascular magnetic re...

DUBLIN--(BUSINESS WIRE)--The "United States Fair-Market Value Compensation Rates for Otorhinolaryngology KOLs" report has been added to ResearchAndMarkets.com's offering. This report presents fair-market value (FMV) hourly and half-day compensation rates for U.S. KOLs - Otorhinolaryngology, by percentiles, with averages, for four (4) levels of Thought Leader influences (rare, international, national and local). Thought Leader Compensation US Otorhinolaryngology These defensible market-based rat...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial...

MIAMI--(BUSINESS WIRE)--The Real Brokerage Inc. (NASDAQ: REAX), a leading real estate technology platform redefining the industry through innovation and culture, today announced that, on Nov. 5, 2025, it reached a settlement in principle in the litigation with its former Chief Financial Officer, Michelle Ressler. The court action has been dismissed by the court. Pursuant to the settlement in principle, Real will make no payment to Ms. Ressler. In addition, pursuant to the settlement in principl...

JACKSONVILLE, Fla.--(BUSINESS WIRE)--FIS launches new Asset Servicing Management Suite, a suite of automated and integrated solutions which help unlock operational efficiency....

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG). The studies met the primary endpoint, with olezarsen achieving a highly statistically significant placebo-adjusted mean reduction in fasting triglyceride (TG) levels of up to 72% at six months. The reductions were sustained through 12 months. Olezarsen showed a highly statist...